vTv Therapeutics Inc.

06/29/2026 | Press release | Distributed by Public on 06/29/2026 14:15

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 26, 2026, vTv Therapeutics Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
(1)Based on the following results of the voting, the Company's stockholders elected the nominees listed below to the Company's Board of Directors, each to serve for a term to expire at the Company's 2027 annual meeting of stockholders or until their successors are duly elected and qualified:
Director Nominee
For
Withheld
Broker Non Votes
Srinivas Akkaraju
720,963 1,938,192 310,535
Raymond Cheong
729,489 1,929,666 310,535
Fahed Al Marzooqi 2,395,229 263,926 310,535
Richard S. Nelson
2,395,013 264,142 310,535
Anne Phillips
905,938 1,753,217 310,535
Paul Sekhri
905,325 1,753,830 310,535
Daniel K. Spiegelman
774,244 1,884,911 310,535
(2)The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified based on the following results of the voting:
For
Against Abstain Broker Non Votes
2,964,869 1,952 2,869 0
(3)The Company's stockholders voted on a nonbinding advisory basis on the compensation paid to the Company's named executive officers as follows:
For
Against Abstain Broker Non Votes
686,535 5,291 1,967,329 310,535
vTv Therapeutics Inc. published this content on June 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 29, 2026 at 20:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]